comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 12:11:31 - browse：77

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Medicare drug price negotiation program allowed for now

entertainment

WSS

Readout LOUD podcast, live from the STAT Breakthrough Summit East

Menendez indictment could see pharma lose a key ally

Why do women spend more than men on medical expenses?

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

Kaiser Permanente unions announce official strike date

Testing GLP

entertainment

comprehensive

leisure time

Heart attack and stroke risk calculators need revising

Bring on the sabbaticals for nurses

Psychedelics group wrestles with new pharma identity

Mirador, a new biotech startup, launches with $400 million

Hepatitis C has a cure — but many Americans still lack access to it

Diabetes management: Digital health tools fall short, study says

Hollywood unions extend contract negotiations for actors

Kaiser Permanente unions announce official strike date

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

What Kate Middleton's cancer revelation might teach the world

hotspot

Researchers use wearables data and AI to predict preterm birth risk

Surgeons perform first xenotransplant using CRISPR'd pig kidney

Testing GLP

How the Dana

Paxlovid should be available without a positive Covid test

Address the ethical violations that led to 'Three Identical Strangers'

focus

hotspot

entertainment

entertainment